A 2024 study in Diabetes Obesity Metabolism , however, showed similar A1C decreases for injectable and oral forms
Many GLP-1 drugs, used to treat diabetes and obesity, cost over $1,000 a month without insurance or discounts
Phase 2 trial data (published in New England Journal of Medicine, 2023 ): 24.2% average weight loss at 48 weeks with 12 mg dose 22.8% with 8 mg dose Placebo group lost 2.1% Most recent Phase 3 trial data (TRIUMPH-4, December 2025): 28.7% average weight loss at 68 weeks with 12 mg dose 26.4% with 9 mg dose 58.6% of participants on 12 mg achieved at least 25% weight loss 39.4% achieved at least 30% weight loss For context: These are the highest weight loss numbers reported in any clinical trial for a pharmacological obesity treatment
Some patients experience relative hypoglycaemiablood glucose lower than their previous baselinewhich can trigger hunger signals as the body adapts to improved glucose control
The drug levels of medications with narrow therapeutic windows (e.g., warfarin) should be monitored closely while on Zepbound
We provide the best semaglutide online programs as well as in-person consultations to ensure that your weight loss journey is successful and safe
